Nephrolytics Secures $2.5M Seed Round to Revolutionize Kidney Care with AI-Driven Innovation

Nephrolytics, Inc., the pioneer behind the AI-powered clinical intelligence platform designed exclusively for nephrology, is proud to announce its recent funding of $2.5 million—a significant milestone that underscores investor confidence in its transformative approach to kidney care. As the medical field continues to face the challenges of rising patient volumes, provider burnout, and nephrologist shortages, Nephrolytics stands out with its purpose-built solution that combines AI, automation, and precision medicine. Central to this innovation is Saya™, an AI-powered clinical co-pilot meticulously engineered to integrate with EMRs, labs, imaging systems, and health information exchanges. Saya™ is unlocking a new era in clinical support by delivering real-time, patient-specific insights, automating documentation through AI-Scribe with capabilities such as generating SOAP notes and automated coding, and offering personalized, evidence-based treatment guidance through Smart Recommendations™, Smart Summary™, and Smart Alerts & Predictive Insights. This funding will accelerate the platform’s mission to convert fragmented data into actionable intelligence, reducing administrative burdens by up to 40% while enhancing coding accuracy by 45%, thereby enabling healthcare providers to focus more on individualized, value-based care. Moreover, the ability of Saya™ to proactively identify risks and offer fast, evidence-based solutions is setting a new standard in proactive nephrology care. Nephrolytics is not simply a tech solution but a clinical transformation engine built by nephrologists, for nephrologists—a mission now further empowered by this new influx of capital to scale its impact across medical practices, large nephrology groups, and accountable care organizations. This funding marks a promising leap forward in pioneering smarter, more efficient kidney care for the future.